Grail raises $390M for multicancer liquid biopsy

2020 02 13 19 55 0762 Dollar Sign Green 400

Menlo Park, CA-based startup Grail has raised an additional $390 million to advance its multicancer blood test, which is being validated for the early detection of 50 different tumor types.

Grail said the new cash infusion came in a series D round that included existing investors such as Illumina, as well as new backers including the Public Sector Pension Investment Board, the Canada Pension Plan Investment Board, and two undisclosed investors.

In addition to Illumina, Grail's investors have included Amazon, Bill Gates, Bezos Expeditions, Bristol-Myers Squibb, and Celgene. The company has raised a total of $1.9 billion since 2016.

Page 1 of 7
Next Page